A major milestone in public health just arrived. The introduction of H.R. 7602, the State of Men’s Health Act, marks a bold federal commitment to improving men’s health outcomes and tackling disparities that have persisted for decades. The AUA is honored to have played a key role in shaping this legislation and supporting the creation of a new Office of Men’s Health, which will coordinate nationwide efforts to improve awareness, prevention, and care.
A big shoutout to Congressman @RepTroyCarter and @RepGregMurphy for introducing and supporting this monumental bill. This is a turning point, and we’re proud to be part of it. #AUAAdvocacy
🔗 Click to learn more about the bill: https://t.co/EPqoOSj8Om
Congratulations to Dominic Collins and Johnathan Yoder on matching into the Vandalia Health CAMC Urology Residency! We are excited to welcome them to our program.
With the final analysis of the last of the 1st line metastatic clear cell RCC trials combination trials it’s still fair to say ‘pick one and use it well’. #GUARDSymposium2025 Ipi/nivo is less good at getting initial control but has less long term toxicity. @brian_rini@OncoAlert
🔥New feature on @urotoday 🔥
When you click on the Journal Club link 👇, you can watch/listen to the discussion AND click "Download Journal Club Slides" to add to your slide deck library
Great for:
- Trainees
- Putting together Grand Rounds talks
- Residency/Fellowship journal clubs
- Etc
We're incredibly proud to congratulate our two graduating Urology residents, Thomas Cato, DO, and Carly Ulrich, DO! Their commitment to excellence and professional growth throughout the program has been exceptional. We can't wait to see all they’ll accomplish next!
We're incredibly proud to congratulate our two graduating Urology residents, Thomas Cato, DO, and Carly Ulrich, DO! Their commitment to excellence and professional growth throughout the program has been exceptional. We can't wait to see all they’ll accomplish next!
At #ASCO25 : New Nectin4/PD1 combo data with response rates similar to EVP in bladder cancer. Also DV/toripalimab is better than chemo (press release). There multiple ways of beating 1st line chemo in UC. As chemo becomes less relevant a key question is around ADC sequencing
Calling all urology professionals! ☎️
We're excited to announce the launch of our Data Research Program (DRP), open to all AUA members. This is your opportunity to drive impactful research using real-world data. 📈
✍️ Submit your Letter of Intent by June 22nd to be considered!
Learn more here! ➡️ https://t.co/lc2otSDEAe
BOND-003 Cohort C Update at #AUA25 ➡️
Intravesical Cretostimogene Grenadenorepvec for HR BCG-unresponsive NMIBC
•75.5% overall CR rate
•64.1% CR at 12 months, 58.3% CR at 24 months📉
•97.3% free from MIBC progression at 24 mo
Just in time for AUA - A high-quality succinct review on contemporary intravesical therapy on NMIBC by the great @saumyg & all ��️ colleagues in @EUplatinum
Beautiful figures too!
A valuable resource for patients & urologists @BladderCancerUS @SUO_YUO
https://t.co/nLhAa3JBq2